About

Jacob S Brenner, MD, PhD, is an Assistant Professor of Medicine in the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania. He is an attending physician in the Medical Intensive Care Unit (MICU) at the Hospital of the University of Pennsylvania. Dr. Brenner co-directs Penn's Center for Targeted Therapeutics & Translational Nanomedicine and teaches nanomedicine and medical entrepreneurship at Penn. His research focuses on the use of nanotechnology and nanomedicine to develop new gene therapy and genetic medicine therapies. His lab, Brenner Bioengineering Lab, has developed the first safe and effective DNA-loaded lipid nanoparticles (DNA-LNPs) for treating a variety of chronic diseases, including monogenic diseases such as cystic fibrosis, hemophilia A, and neurofibromatosis, as well as rare non-monogenic diseases like pulmonary hypertension and bronchopulmonary dysplasia. The lab also works on mRNA-LNPs for acute critical illnesses, investigating treatments for conditions such as stroke, ARDS, and sepsis. Additionally, Dr. Brenner's research includes studying the toxicology of nanomedicine and gene therapy, understanding the mechanisms of side effects, and engineering solutions to mitigate adverse effects. His work employs tools from complexity science and statistical physics to analyze disease dynamics, contributing to the understanding of diseases as dynamical systems.

Research topics

• Medicine
• Biology
• Chemistry
• Pharmacology
• Virology

Recent grants

• Nanonscale drug carriers for the treatment of acute respiratory distress syndrome

  NIH · $746k · 2017–2022

• Targeted Drug Delivery For Acute Respiratory Distress Syndrome

  NIH · $115k · 2015–2017

• Controlling complement to unleash nanomedicine for acute critical illnesses

  NIH · $2.0M · 2022–2026

• Controlling complement to unleash nanomedicine for acute critical illnesses

  NIH · $695k · 2022–2026

• Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillaries

  NIH · $1.6M · 2020–2025

Frequent coauthors

• Vladimir R. Muzykantov

  Translational Therapeutics (United States)

  178 shared

• Jacob W. Myerson

  California University of Pennsylvania

  123 shared

• Patrick M. Glassman

  Temple University

  91 shared

• Oscar A. Marcos‐Contreras

  University of Pennsylvania

  85 shared

• Vladimir V. Shuvaev

  Translational Therapeutics (United States)

  80 shared

• Jia Nong

  California University of Pennsylvania

  68 shared

• Elizabeth D. Hood

  Translational Therapeutics (United States)

  63 shared

• Marco E. Zamora

  Translational Therapeutics (United States)

  60 shared

Labs

• Brenner Bioengineering LabPI